CCL

Összesen 7 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM126277
035-os BibID:(scopus)85201493485
Első szerző:De Brouwer, Edward
Cím:Machine-learning-based prediction of disability progression in multiple sclerosis : an observational, international, multi-center study / De Brouwer E., Becker T., Werthen-Brabants L., Dewulf P., Iliadis D., Dekeyser C., Laureys G., Van Wijmeersch B., Popescu V., Dhaene T., Deschrijver D., Waegeman W., De Baets B., Stock M., Horakova D., Patti F., Izquierdo G., Eichau S., Girard M., Prat A., Lugaresi A., Grammond P., Kalincik T., Alroughani R., Grand'Maison F., Skibina O., Terzi M., Lechner-Scott J., Gerlach O., Khoury S. J., Cartechini E., Van Pesch V., Sa M. J., Weinstock-Guttman B., Blanco Y., Ampapa R., Spitaleri D., Solaro C., Maimone D., Soysal A., Iuliano G., Gouider R., Castillo-Trivino T., Sánchez-Menoyo J. L., Laureys G., van der Walt A., Oh J., Aguera-Morales E., Altintas A., Al-Asmi A., de Gans K., Fragoso Y., Csepany T., Hodgkinson S., Deri N., Al-Harbi T., Taylor B., Gray O., Lalive P., Rozsa C., McGuigan C., Kermode A., Sempere A. P., Mihaela S., Simo M., Hardy T., Decoo D., Hughes S., Grigoriadis N., Sas A., Vella N., Moreau Y., Peeters L.
Dátum:2024
ISSN:2767-3170
Megjegyzések:Background Disability progression is a key milestone in the disease evolution of people with multiple sclerosis (PwMS). Prediction models of the probability of disability progression have not yet reached the level of trust needed to be adopted in the clinic. A common benchmark to assess model development in multiple sclerosis is also currently lacking. Methods Data of adult PwMS with a follow-up of at least three years from 146 MS centers, spread over 40 countries and collected by the MSBase consortium was used. With basic inclusion criteria for quality requirements, it represents a total of 15, 240 PwMS. External validation was performed and repeated five times to assess the significance of the results. Transparent Reporting for Individual Prognosis Or Diagnosis (TRIPOD) guidelines were followed. Confirmed disability progression after two years was predicted, with a confirmation window of six months. Only routinely collected variables were used such as the expanded disability status scale, treatment, relapse information, and MS course. To learn the probability of disability progression, state-of-the-art machine learning models were investigated. The discrimination performance of the models is evaluated with the area under the receiver operator curve (ROC-AUC) and under the precision recall curve (AUC-PR), and their calibration via the Brier score and the expected calibration error. All our preprocessing and model code are available at https://gitlab.com/edebrouwer/ms_benchmark, making this task an ideal benchmark for predicting disability progression in MS. Findings Machine learning models achieved a ROC-AUC of 0?71 ? 0?01, an AUC-PR of 0?26 ? 0?02, a Brier score of 0?1 ? 0?01 and an expected calibration error of 0?07 ? 0?04. The history of disability progression was identified as being more predictive for future disability progression than the treatment or relapses history. Conclusions Good discrimination and calibration performance on an external validation set is achieved, using only routinely collected variables. This suggests machine-learning models can reliably inform clinicians about the future occurrence of progression and are mature for a clinical impact study.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Machine learning
disability progression
multiple sclerosis
Megjelenés:PLOS Digital Health. - 3 : 7 (2024), p. 1-25. -
További szerzők:Becker, Thijs Werthen-Brabants, Lorin Dewulf, Pieter Iliadis, Dimitrios Dekeyser, Cathérine Laureys, Guy Wijmeersch, Bart Van Popescu, Veronica Dhaene, Tom Deschrijver, Dirk Waegeman, Willem De Baets, Bernard Stock, Michael J. Horakova, Dana Patti, Francesco Izquierdo, Guillermo Eichau, Sara Girard, Marc Prat, Alexandre Lugaresi, Alessandra Grammond, Pierre Kalincik, Tomas Alroughani, Raed Grand'Maison, Francois Skibina, Olga Terzi, Murat Lechner-Scott, Jeannette Gerlach, Oliver Khoury, Samia J. Cartechini, Elisabetta Pesch, Vincent van Sá, Maria José Weinstock-Guttman, Bianca Blanco, Yolanda Ampapa, Radek Spitaleri, Daniele Solaro, Claudio Maimone, Davide Soysal, Aysun Iuliano, Gerardo Gouider, Riadh Castillo Triviño, Tamara Sanchez-Menoyo, Jose Laureys, Guy (Universitary Hospital Ghent) Walt, Anneke van der Oh, Jiwon Aguera-Morales, Eduardo Altintas, Ayse Al-Asmi, Abdullah de Gans, Koen Fragoso, Yara Csépány Tünde (1956-) (neurológus, pszichiáter) Hodgkinson, Suzanne Deri, Norma Al-Harbi, Talal Taylor, Bruce V. Gray, Orla Lalive, Patrice H. Rózsa Csilla McGuigan, Christopher Kermode, Allan G. Sempere, Perez A. Mihaela, Simu Simó Magdolna Hardy, Todd A. Decoo, Danny Hughes, Stella Grigoriadis, Nikolaos Sas Attila Vella Norbert Moreau, Yves Peeters, Liesbet
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM107545
035-os BibID:(Scopus)85148460657 (WoS)000952991100026
Első szerző:Diouf, Ibrahima
Cím:Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis / Diouf Ibrahima, Malpas Charles B., Sharmin Sifat, Roos Izanne, Horakova Dana, Havrdova Eva Kubala, Patti Francesco, Shaygannejad Vahid, Ozakbas Serkan, Izquierdo Guillermo, Eichau Sara, Onofrj Marco, Lugaresi Alessandra, Alroughani Raed, Prat Alexandre, Girard Marc, Duquette Pierre, Terzi Murat, Boz Cavit, Grand'Maison Francois, Hamdy Sherif, Sola Patrizia, Ferraro Diana, Grammond Pierre, Turkoglu Recai, Buzzard Katherine, Skibina Olga, Yamout Bassem, Altintas Ayse, Gerlach Oliver, van Pesch Vincent, Blanco Yolanda, Maimone Davide, Lechner-Scott Jeannette, Bergamaschi Roberto, Karabudak Rana, Iuliano Gerardo, McGuigan Chris, Cartechini Elisabetta, Barnett Michael, Hughes Stella, Sa Maria José, Solaro Claudio, Kappos Ludwig, Ramo-Tello Cristina, Cristiano Edgardo, Hodgkinson Suzanne, Spitaleri Daniele, Soysal Aysun, Petersen Thor, Slee Mark, Butler Ernest, Granella Franco, de Gans Koen, McCombe Pamela, Ampapa Radek, Van Wijmeersch Bart, van der Walt Anneke, Butzkueven Helmut, Prevost Julie, Sinnige L. G. F., Sanchez-Menoyo Jose Luis, Vucic Steve, Laureys Guy, Van Hijfte Liesbeth, Khurana Dheeraj, Macdonell Richard, Gouider Riadh, Castillo-Trivino Tamara, Gray Orla, Aguera-Morales Eduardo, Al-Asmi Abdullah, Shaw Cameron, Deri Norma, Al-Harbi Talal, Fragoso Yara, Csepany Tunde, Perez Sempere Angel, Trevino-Frenk Irene, Schepel Jan, Moore Fraser, Kalincik Tomas
Dátum:2023
ISSN:1351-5101
Megjegyzések:Background This study assessed the effect of patient characteristics on the response to disease modifying therapy (DMT) in in multiple sclerosis (MS). Methods We extracted data from 61,810 patients from 135 centres across 35 countries from the MSBase registry. The selection criteria were: clinically isolated syndrome or definite MS; follow-up ?1 year; ?3 EDSS scores; and with ?1 score recorded per year. Marginal structural models with interaction terms were used to compare the hazards of 12-month confirmed worsening and improvement of disability, and the incidence of relapses between treated and untreated patients stratified by their characteristics. Results Among 24,344 patients with relapsing MS, those on DMTs experienced 48% reduction in relapse incidence (hazard ratio (HR)=0.52, 95%CI=0.45-0.60), 46% lower risk of disability worsening (HR=0.54, 95%CI=0.41-0.71) and 32% greater chance of disability improvement (HR=1.32, 95%CI=1.09-1.59). The effect of DMTs on EDSS worsening and improvement and the risk of relapses was attenuated with more severe disability. The magnitude of the effect of DMT on suppressing relapses declined with higher prior relapse rate and prior cerebral MRI activity. We did not find any evidence for the effect of age on the effectiveness of DMT. After inclusion of 1985 participants with progressive MS, the effect of DMT on disability mostly depended on MS phenotype, whereas its effect on relapses was driven mainly by prior relapse activity. Conclusions DMT is generally most effective among patients with lower disability and in relapsing MS phenotypes. There is no evidence attenuation of the effect of DMT with age.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Journal Of Neurology. - 30 : 4 (2023), p. 1014-1024. -
További szerzők:Malpas, Charles B. Sharmin, Sifat Roos, Izanne Horakova, Dana Havrdova, Eva Patti, Francesco Shaygannejad, Vahid Ozakbas, Serkan Izquierdo, Guillermo Eichau, Sara Onofrj, Marco Lugaresi, Alessandra Alroughani, Raed Prat, Alexandre Girard, Marc Duquette, Pierre Terzi, Murat Boz, Cavit Grand'Maison, Francois Hamdy, Sherif Sola, Patrizia Ferraro, Diana Grammond, Pierre Turkoglu, Recai Buzzard, Katherine Skibina, Olga Yamout, Bassem Altintas, Ayse Gerlach, Oliver Pesch, Vincent van Blanco, Yolanda Maimone, Davide Lechner-Scott, Jeannette Bergamaschi, Roberto Karabudak, Rana Iuliano, Gerardo McGuigan, Christopher Cartechini, Elisabetta Barnett, Michael Hughes, Stella Sá, Maria José Solaro, Claudio Kappos, Ludwig Ramo-Tello, Cristina Cristiano, Edgardo Hodgkinson, Suzanne Spitaleri, Daniele Soysal, Aysun Petersen, Thor Slee, Mark Butler, Ernest Granella, Franco de Gans, Koen McCombe, Pamela Ampapa, Radek Wijmeersch, Bart Van Walt, Anneke van der Butzkueven, Helmut Prevost, Julie Sinnige, L. G. F. Sanchez-Menoyo, Jose Vucic, Steve Laureys, Guy Van Hijfte, Liesbeth Khurana, Dheeraj Macdonell, Richard Gouider, Riadh Castillo Triviño, Tamara Gray, Orla Aguera-Morales, Eduardo Al-Asmi, Abdullah Shaw, Cameron Deri, Norma Al-Harbi, Talal Fragoso, Yara Csépány Tünde (1956-) (neurológus, pszichiáter) Perez Sempere, Angel Trevino-Frenk, Irene Schepel, Jan Moore, Fraser Kalincik, Tomas
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM126432
035-os BibID:(WoS)001077004600002 (Scopus)85181761016
Első szerző:Li, Ying
Cím:Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis : recruitment challenges, potential bias, and statistical strategies / Li Y., Saul A., Taylor B., Ponsonby A. L., Simpson-Yap S., Blizzard L., Broadley S., Lechner-Scott J., Ausimmune/AusLong Investigators Group, Karabudak R., Patti F., Eichau S., Onofrj M., Ozakbas S., Horakova D., Kubala Havrdova E., Grand'Maison F., Alroughani R., Gerlach O., Amato M. P., Altintas A., Girard M., Duquette P., Blanco Y., Ramo-Tello C., Laureys G., Kalincik T., Khoury S. J., Shaygannejad V., Etemadifar M., Singhal B., Mrabet S., Foschi M., Habek M., John N., Hughes S., McCombe P., Ampapa R., van der Walt A., Butzkueven H., de Gans K., McGuigan C., Oreja-Guevara C., Sa M. J., Petersen T., Al-Harbi T., Sempere A. P., Van Wijmeersch B., Grigoriadis N., Prevost J., Gray O., Castillo-Trivino T., Macdonell R., Lugaresi A., Sajedi S. A., MSBase, van der Mei I.
Dátum:2024
ISSN:0340-5354
Megjegyzések:It is unknown whether the currently known risk factors of multiple sclerosis reflect the etiology of progressive-onset multiple sclerosis (POMS) as observational studies rarely included analysis by type of onset. We designed a case-control study to examine associations between environmental factors and POMS and compared effect sizes to relapse-onset MS (ROMS), which will offer insights into the etiology of POMS and potentially contribute to prevention and intervention practice. This study utilizes data from the Primary Progressive Multiple Sclerosis (PPMS) Study and the Australian Multi-center Study of Environment and Immune Function (the AusImmune Study). This report outlines the conduct of the PPMS Study, whether the POMS sample is representative, and the planned analysis methods. The study includes 155 POMS, 204 ROMS, and 558 controls. The distributions of the POMS were largely similar to Australian POMS patients in the MSBase Study, with 54.8% female, 85.8% POMS born before 1970, mean age of onset of 41.44 ? 8.38 years old, and 67.1% living between 28.9 and 39.4? S. The POMS were representative of the Australian POMS population. There are some differences between POMS and ROMS/controls (mean age at interview: POMS 55 years vs. controls 40 years; sex: POMS 53% female vs. controls 78% female; location of residence: 14.3% of POMS at a latitude ? 28.9?S vs. 32.8% in controls), which will be taken into account in the analysis. We discuss the methodological issues considered in the study design, including prevalence-incidence bias, cohort effects, interview bias and recall bias, and present strategies to account for it. Associations between exposures of interest and POMS/ROMS will be presented in subsequent publications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Bias
Case-control
Environmental factors
Progressive-onset multiple sclerosis
Subject recruitment.
Megjelenés:Journal Of Neurology. - 271 : 1 (2024), p. 472-485. -
További szerzők:Saul, Alice Taylor, Bruce V. Ponsonby, Anne-Louise Simpson-Yap, Steve Blizzard, Leigh Broadley, Simon Lechner-Scott, Jeannette Karabudak, Rana Patti, Francesco Eichau, Sara Onofrj, Marco Ozakbas, Serkan Horakova, Dana Kubala Havrdova, Eva Grand'Maison, Francois Alroughani, Raed Gerlach, Oliver Amato, Maria Pia Altintas, Ayse Girard, Marc Duquette, Pierre Blanco, Yolanda Ramo-Tello, Cristina Laureys, Guy Kalincik, Tomas Khoury, Samia J. Shaygannejad, Vahid Etemadifar, Masoud Singhal, Bhim Mrabet, Saloua Foschi, Matteo Habek, Mario John, Nevin Hughes, Stella McCombe, Pamela Ampapa, Radek Walt, Anneke van der Butzkueven, Helmut de Gans, Koen McGuigan, Christopher Oreja-Guevara, Celia Sá, Maria José Petersen, Thor Al-Harbi, Talal Sempere, Perez A. Wijmeersch, Bart Van Grigoriadis, Nikolaos Prevost, Julie Gray, Orla Castillo Triviño, Tamara Macdonell, Richard Lugaresi, Alessandra Sajedi, Seyed Aidin Mei, Ingrid van der Csépány Tünde (1956-) (neurológus, pszichiáter) Ausimmune/AusLong Investigators Group MSBase Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM135460
035-os BibID:(Scopus)105002792941 (WoS)001470351300001
Első szerző:Müller, Jannis
Cím:Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis / Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Dana Horakova, Bianca Weinstock-Guttman, Vahid Shaygannejad, Masoud Etemadifar, Raed Alroughani, Francesco Patti, Sara Eichau, Alexandre Prat, Alessandra Lugaresi, Valentina Tomassini, Allan G. Kermode, Maria Pia Amato, Recai Turkoglu, Ayse Altintas, Katherine Buzzard, Aysun Soysal, Anneke van der Walt, Helmut Butzkueven, Yolanda Blanco, Oliver Gerlach, Samia J. Khoury, Michael Barnett, Nevin John, Jeannette Lechner-Scott, Matteo Foschi, Andrea Surcinelli, Vincent van Pesch, Julie Prevost, Maria Jose Sa, Davide Maimone, Marie D'hooghe, Stella Hughes, Suzanne Hodgkinson, Chris McGuigan, Elisabetta Cartechini, Bruce Taylor, Daniele Spitaleri, Mark Slee, Pamela McCombe, Bassem Yamout, Pascal Benkert, Jens Kuhle, Ludwig Kappos, Izanne Roos, Tomas Kalincik, PGCertBiostat, MSBase Study Group
Dátum:2025
Megjegyzések:Importance: Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective: To compare various definitions of PIRA. Design, setting, and participants: This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure: Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main outcome and measure: For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ?5 years). Results: Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and relevance: Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:JAMA Neurology. - 82 : 6 (2025), p. 614-625. -
További szerzők:Sharmin, Sifat Lorscheider, Johannes Ozakbas, Serkan Karabudak, Rana Horakova, Dana Weinstock-Guttman, Bianca Shaygannejad, Vahid Etemadifar, Masoud Alroughani, Raed Patti, Francesco Eichau, Sara Prat, Alexandre Lugaresi, Alessandra Tomassini, Valentina Kermode, Allan G. Amato, Maria Pia Turkoglu, Recai Altintas, Ayse Buzzard, Katherine Soysal, Aysun Walt, Anneke van der Butzkueven, Helmut Blanco, Yolanda Gerlach, Oliver Khoury, Samia J. Barnett, Michael John, Nevin Lechner-Scott, Jeannette Foschi, Matteo Surcinelli, Andrea Pesch, Vincent van Prevost, Julie Sa, Maria Jose Maimone, Davide D'hooghe, Marie Hughes, Stella Hodgkinson, Suzanne McGuigan, Christopher Cartechini, Elisabetta Taylor, Bruce V. Spitaleri, Daniele Slee, Mark McCombe, Pamela Yamout, Bassem Benkert, Pascal Kuhle, Jens Kappos, Ludwig Roos, Izanne Kalincik, Tomas Csépány Tünde (1956-) (neurológus, pszichiáter) MSBase Study Group PGCertBiostat
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM132947
035-os BibID:(scopus)105011413182 (wos)001536298500003
Első szerző:Pirmani, Ashkan
Cím:Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data / Pirmani Ashkan, De Brouwer Edward, Arany Ádám, Oldenhof Martijn, Passemiers Antoine, Faes Axel, Kalincik Tomas, Ozakbas Serkan, Gouider Riadh, Willekens Barbara, Horakova Dana, Havrdova Eva Kubala, Patti Francesco, Prat Alexandre, Lugaresi Alessandra, Tomassini Valentina, Grammond Pierre, Cartechini Elisabetta, Roos Izanne, Boz Cavit, Alroughani Raed, Amato Maria Pia, Buzzard Katherine, Lechner-Scott Jeannette, Guimaraes Joana, Solaro Claudio, Gerlach Oliver, Soysal Aysun, Kuhle Jens, Sanchez-Menoyo Jose Luis, Spitaleri Daniele, Csepany Tunde, Van Wijmeersch Bart, Ampapa Radek, Prevost Julie, Khoury Samia J., Van Pesch Vincent, John Nevin, Maimone Davide, Weinstock-Guttman Bianca, Laureys Guy, McCombe Pamela, Blanco Yolanda, Altintas Ayse, Al-Asmi Abdullah, Garber Justin, Van der Walt Anneke, Butzkueven Helmut, de Gans Koen, Rozsa Csilla, Taylor Bruce, Al-Harbi Talal, Sas Attila, Rajda Cecilia, Gray Orla, Decoo Danny, Carroll William M., Kermode Allan G., Fabis-Pedrini Marzena, Mason Deborah, Perez-Sempere Angel, Simu Mihaela, Shuey Neil, Singhal Bhim, Cauchi Marija, Hardy Todd A., Ramanathan Sudarshini, Lalive Patrice, Sirbu Carmen-Adella, Hughes Stella, Castillo Trivino Tamara, Peeters Liesbet M., Moreau Yves
Dátum:2025
ISSN:2398-6352
Megjegyzések:Early prediction of disability progression in multiple sclerosis (MS) remains challenging despite its critical importance for therapeutic decision-making. We present the first systematic evaluation of personalized federated learning (PFL) for 2-year MS disability progression prediction, leveraging multi-center real-world data from over 26,000 patients. While conventional federated learning (FL) enables privacy-aware collaborative modeling, it remains vulnerable to institutional data heterogeneity. PFL overcomes this challenge by adapting shared models to local data distributions without compromising privacy. We evaluated two personalization strategies: a novel AdaptiveDualBranchNet architecture with selective parameter sharing, and personalized fine-tuning of global models, benchmarked against centralized and client-specific approaches. Baseline FL underperformed relative to personalized methods, whereas personalization significantly improved performance, with personalized FedProx and FedAVG achieving ROC-AUC scores of 0.8398 ? 0.0019 and 0.8384 ? 0.0014, respectively. These findings establish personalization as critical for scalable, privacy-aware clinical prediction models and highlight its potential to inform earlier intervention strategies in MS and beyond.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:npj Digital Medicine. - 8 : 1 (2025), p. 1-15. -
További szerzők:De Brouwer, Edward Arany Ádám Oldenhof, Martijn Passemiers, Antoine Faes, Axel Kalincik, Tomas Ozakbas, Serkan Gouider, Riadh Willekens, Barbara Horakova, Dana Havrdova, Eva Patti, Francesco Prat, Alexandre Lugaresi, Alessandra Tomassini, Valentina Grammond, Pierre Cartechini, Elisabetta Roos, Izanne Boz, Cavit Alroughani, Raed Amato, Maria Pia Buzzard, Katherine Lechner-Scott, Jeannette Guimaraes, Joana Solaro, Claudio Gerlach, Oliver Soysal, Aysun Kuhle, Jens Sanchez-Menoyo, Jose Spitaleri, Daniele Csépány Tünde (1956-) (neurológus, pszichiáter) Wijmeersch, Bart Van Ampapa, Radek Prevost, Julie Khoury, Samia J. Pesch, Vincent van John, Nevin Maimone, Davide Weinstock-Guttman, Bianca Laureys, Guy (Universitary Hospital Ghent) McCombe, Pamela Blanco, Yolanda Altintas, Ayse Al-Asmi, Abdullah Garber, Justin Walt, Anneke van der Butzkueven, Helmut de Gans, Koen Rózsa Csilla Taylor, Bruce V. Al-Harbi, Talal Sas Attila Rajda Cecília Gray, Orla Decoo, Danny Carroll, William M. Kermode, Allan G. Fabis-Pedrini, Marzena Mason, Deborah Perez-Sempere, Angel Simu, Mihaela Shuey, Neil Singhal, Bhim Cauchi, Marija Hardy, Todd A. Ramanathan, Sudarshini Lalive, Patrice H. Sirbu, Carmen-Adella Hughes, Stella Castillo Triviño, Tamara Peeters, Liesbet Moreau, Yves
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM114473
035-os BibID:(Scopus)85148502832 (WoS)000951172400001
Első szerző:Roos, Izanne
Cím:Comparative effectiveness in multiple sclerosis : A methodological comparison / Roos Izanne, Diouf Ibrahima, Sharmin Sifat, Horakova Dana, Havrdova Eva Kubala, Patti Francesco, Shaygannejad Vahid, Ozakbas Serkan, Izquierdo Guillermo, Eichau Sara, Onofrj Marco, Lugaresi Alessandra, Alroughani Raed, Prat Alexandre, Girard Marc, Duquette Pierre, Terzi Murat, Boz Cavit, Grand'Maison Francois, Sola Patrizia, Ferraro Diana, Grammond Pierre, Turkoglu Recai, Buzzard Katherine, Skibina Olga, Yamout Bassem, Altintas Ayse, Gerlach Oliver, van Pesch Vincent, Blanco Yolanda, Maimone Davide, Lechner-Scott Jeannette, Bergamaschi Roberto, Karabudak Rana, McGuigan Chris, Cartechini Elisabetta, Barnett Michael, Hughes Stella, Sa Maria José, Solaro Claudio, Ramo-Tello Cristina, Hodgkinson Suzanne, Spitaleri Daniele, Soysal Aysun, Petersen Thor, Granella Franco, de Gans Koen, McCombe Pamela, Ampapa Radek, Van Wijmeersch Bart, van der Walt Anneke, Butzkueven Helmut, Prevost Julie, Sanchez-Menoyo Jose Luis, Laureys Guy, Gouider Riadh, Castillo-Trivino Tamara, Gray Orla, Aguera-Morales Eduardo, Al-Asmi Abdullah, Shaw Cameron, Deri Norma, Al-Harbi Talal, Fragoso Yara, Csepany Tunde, Sempere Angel Perez, Trevino-Frenk Irene, Schepel Jan, Moore Fraser, Malpas Charles, Kalincik Tomas, MSBase study group
Dátum:2023
ISSN:1352-4585
Megjegyzések:Background: In the absence of evidence from randomised controlled trials, observational data can be used to emulate clinical trials and guide clinical decisions. Observational studies are, however, susceptible to confounding and bias. Among the used techniques to reduce indication bias are propensity score matching and marginal structural models. Objective: To use the comparative effectiveness of fingolimod vs natalizumab to compare the results obtained with propensity score matching and marginal structural models. Methods: Patients with clinically isolated syndrome or relapsing remitting MS who were treated with either fingolimod or natalizumab were identified in the MSBase registry. Patients were propensity score matched, and inverse probability of treatment weighted at six monthly intervals, using the following variables: age, sex, disability, MS duration, MS course, prior relapses, and prior therapies. Studied outcomes were cumulative hazard of relapse, disability accumulation, and disability improvement. Results: 4608 patients (1659 natalizumab, 2949 fingolimod) fulfilled inclusion criteria, and were propensity score matched or repeatedly reweighed with marginal structural models. Natalizumab treatment was associated with a lower probability of relapse (PS matching: HR 0.67 [95% CI 0.62-0.80]; marginal structural model: 0.71 [0.62-0.80]), and higher probability of disability improvement (PS matching: 1.21 [1.02 -1.43]; marginal structural model 1.43 1.19 -1.72]). There was no evidence of a difference in the magnitude of effect between the two methods. Conclusions: The relative effectiveness of two therapies can be efficiently compared by either marginal structural models or propensity score matching when applied in clearly defined clinical contexts and in sufficiently powered cohorts.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Observational
causal inference
multiple sclerosis
Megjelenés:Multiple Sclerosis. - 29 : 3 (2023), p. 326-332. -
További szerzők:Diouf, Ibrahima Sharmin, Sifat Horakova, Dana Havrdova, Eva Patti, Francesco Shaygannejad, Vahid Ozakbas, Serkan Izquierdo, Guillermo Eichau, Sara Onofrj, Marco Lugaresi, Alessandra Alroughani, Raed Prat, Alexandre Girard, Marc Duquette, Pierre Terzi, Murat Boz, Cavit Grand'Maison, Francois Sola, Patrizia Ferraro, Diana Grammond, Pierre Turkoglu, Recai Buzzard, Katherine Skibina, Olga Yamout, Bassem Altintas, Ayse Gerlach, Oliver Pesch, Vincent van Blanco, Yolanda Maimone, Davide Lechner-Scott, Jeannette Bergamaschi, Roberto Karabudak, Rana McGuigan, Christopher Cartechini, Elisabetta Barnett, Michael Hughes, Stella Sá, Maria José Solaro, Claudio Ramo-Tello, Cristina Hodgkinson, Suzanne Spitaleri, Daniele Soysal, Aysun Petersen, Thor Granella, Franco de Gans, Koen McCombe, Pamela Ampapa, Radek Wijmeersch, Bart Van Walt, Anneke van der Butzkueven, Helmut Prevost, Julie Sanchez-Menoyo, Jose Laureys, Guy Gouider, Riadh Castillo Triviño, Tamara Gray, Orla Aguera-Morales, Eduardo Al-Asmi, Abdullah Shaw, Cameron Deri, Norma Al-Harbi, Talal Fragoso, Yara Csépány Tünde (1956-) (neurológus, pszichiáter) Sempere, Perez A. Trevino-Frenk, Irene Schepel, Jan Moore, Fraser Malpas, Charles Kalincik, Tomas MSBase Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM135464
035-os BibID:(Scopus)105029267510 (WoS)001679383200001
Első szerző:Souissi, Amira
Cím:Effect of late-onset on multiple sclerosis phenotype and outcome : evidence from a multi-national registry / Amira Souissi, Francesco Patti, Tim Spelman, Clara Chisari, Amina Gargouri, Nevin John, Allan G. Kermode, Tomas Kalincik, Helmut Butzkueven, Seyed Aidin Sajedi, Jeannette Lechner?Scott, Izanne Roos, Guy Laureys, Bruce Taylor, Raed Alroughani, Samia J. Khoury, Richard Macdonell, Bianca Weinstock?Guttman, Eva Kubala Havrdova, Davide Maimone, Stephen Reddel, Marzena Fabis?Pedrini, Barbara Willekens, Abdorreza Naser Moghadasi, Patrice Lalive, Alessandra Lugaresi, Serkan Ozakbas, Claudio Solaro, Simón Cárdenas?Robledo, Vahid Shaygannejad, Masoud Etemadifar, Cavit Boz, Sara Eichau, Valentina Tomassini, Murat Terzi, Alexandre Prat45 · Mario Habek46 · Yolanda Blanco47 · Ayse Altintas48 · Oliver Gerlach49,50 · Recai Turkoglu51 · Katherine Buzzard52 · Olga Skibina53,54,55 · Aysun Soysal56 · Anneke van der Walt, Stella Hughes, Vincent van Pesch, Matteo Foschi, Andrea Surcinelli, Julie Prevost, Cristina Ramo?Tello, Chris McGuigan, Maria Jose Sa, Jens Kuhle, Daniele Spitaleri, Bhim Singhal, Radek Ampapa, Koen de Gans, Thor Petersen, Mihaela Simu, Emmanuelle Lapointe, Jose Luis Sanchez?Menoyo, Orla Gray, Justin Garber, Eduardo Aguera?Morales, Katrin Gross?Paju, Tamara Castillo?Triviño, Abdullah Al?Asmi, Nikolaos Grigoriadis, Jihad Inshasi, Talal Al?Harbi, Todd A. Hardy, Sudarshini Ramanathan, Melissa Cambron, Neil Shuey, Angel Perez sempere, Tunde Csepany, Irene Treviño?Frenk, Csilla Rozsa, Marija Cauchi, Rana Karabudak, Saloua Mrabet, Riadh Gouider
Dátum:2026
ISSN:0340-5354
Megjegyzések:Background Multiple Sclerosis (MS) severity is influenced by several factors. Understanding the impact of age at disease onset may help to better characterize clinical and disease features across age groups. This study aimed to characterize the clinical features and disability outcomes of late-onset MS (LOMS) and very late-onset MS (vLOMS), compared to adultonset MS (AOMS). Methods We conducted an observational study using data from the MSBase registry and categorized patients based on age at MS onset: AOMS (18?39 years), transition onset (40?49 years), LOMS (50?59 years), and vLOMS (?60 years). Disease progression was assessed using the 24 week confirmed disability progression, EDSS4 and 6 milestones, conversion to secondary progressive MS(SPMS), and the first progression independent of relapse activity (PIRA) event. Cox proportional hazard regression models were used to determine unadjusted hazard ratios(HR), and propensity score inverse probability of treatment weighting(PS-IPTW) balanced covariate distributions. Results Among 81,236 patients, 5.2% had LOMS and 1% had vLOMS. Primary progressive MS was more frequent in LOMS and vLOMS (21.7 and 24%, respectively). Patients with LOMS and vLOMS had a significantly increased risk of 24 week confirmed disability progression (HR:LOMS=1.39, vLOMS=1.80), EDSS 4 (HR:LOMS=2.14, vLOMS=2.95), EDSS 6 (HR:LOMS=2.33, vLOMS=6.33), SPMS (HR:LOMS=1.62, vLOMS=2.38), and first PIRA event (HR:LOMS=2.12, vLOMS=2.93). Conclusion LOMS and vLOMS exhibited a more progressive disease onset and higher disability milestones compared with AOMS.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Multiple Sclerosis
Prognosis
Aging
Progression
Immunosenescence
Megjelenés:Journal Of Neurology. - 273 : 2 (2026), p. 1-15. -
További szerzők:Patti, Francesco Spelman, Tim Chisari, Clara Gargouri, Amina John, Nevin Kermode, Allan G. Kalincik, Tomas Butzkueven, Helmut Sajedi, Seyed Aidin Lechner-Scott, Jeannette Roos, Izanne Laureys, Guy Taylor, Bruce V. Alroughani, Raed Khoury, Samia J. Macdonell, Richard Weinstock-Guttman, Bianca Havrdova, Eva Maimone, Davide Reddel, Stephen Fabis-Pedrini, Marzena Willekens, Barbara Moghadasi, Abdorreza Naser Lalive, Patrice H. Lugaresi, Alessandra Ozakbas, Serkan Solaro, Claudio Cárdenas-Robledo, Simón Shaygannejad, Vahid Etemadifar, Masoud Boz, Cavit Eichau, Sara Tomassini, Valentina Terzi, Murat Prat, Alexandre Habek, Mario Blanco, Yolanda Altintas, Ayse Gerlach, Oliver Turkoglu, Recai Buzzard, Katherine Skibina, Olga Soysal, Aysun Walt, Anneke van der Hughes, Stella Pesch, Vincent van Foschi, Matteo Surcinelli, Andrea Prevost, Julie Ramo-Tello, Cristina McGuigan, Christopher Sa, Maria Jose Kuhle, Jens Spitaleri, Daniele Singhal, Bhim Ampapa, Radek Gans, Koen de Petersen, Thor Simu, Mihaela Lapointe, Emmanuelle Sanchez-Menoyo, Jose Gray, Orla Garber, Justin Aguera-Morales, Eduardo Gross-Paju, Katrin Castillo Triviño, Tamara Al-Asmi, Abdullah Grigoriadis, Nikolaos Inshasi, Jihad Al-Harbi, Talal Hardy, Todd A. Ramanathan, Sudarshini Cambron, Melissa Shuey, Neil Sempere, Perez A. Csépány Tünde (1956-) (neurológus, pszichiáter) Trevino-Frenk, Irene Rózsa Csilla Cauchi, Marija Karabudak, Rana Mrabet, Saloua Gouider, Riadh
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v10.11.18-SNAPSHOT © 2024 Monguz kft. Minden jog fenntartva.